In this study, we used a quantitative assay to measure the concentration-dependent effects of antivirals on extracellular hepatitis B virus (HBV) DNA as well as on different cytoplasmic and nuclear forms of HBV DNA that participate in HBV replication. HBV recombinant baculovirus, which efficiently delivers the HBV genome to HepG2 cells, was used for this study because (i) antivirals can be administered prior to initiation of HBV infection or after HBV infection and (ii) sufficiently high HBV replication levels are achieved that HBV covalently closed circular (CCC) DNA can be easily detected and individual HBV DNA species can be quantitatively analyzed separately from total HBV DNA. The results showed that the levels of HBV replicative intermediate and extracellular DNA decreased in a concentration-dependent fashion following antiviral treatment. The 50% effective concentration (EC 50 ) and EC 90 values and the Hill slopes differed for the different HBV DNA species analyzed. The data clearly indicated that (i) nuclear HBV DNAs are more resistant to antiviral therapy than cytoplasmic or extracellular HBV DNAs and (ii) nuclear HBV CCC DNA is more resistant than the nuclear relaxed circular form. This report presents the first in vitro comparison of the effects of two antivirals administered prior to initiation of HBV infection and the first thorough in vitro quantitative study of concentration-dependent antiviral effects on HBV CCC DNA.
Hepatitis B virus (HBV) is a member of the hepadnavirus family that includes human HBV (8) , woodchuck hepatitis virus (49) , ground squirrel hepatitis virus (28) , and duck HBV (DHBV) (32) . These viruses replicate primarily in hepatocytes of their respective hosts and can establish chronic infections. Hepadnaviruses have a unique genomic organization and a distinctive strategy for replication (14) . Virion DNA synthesis occurs in the cytoplasm of the infected cells inside the viral nucleocapsid particles. Transcription of the 1.1-genome-sized (3.5-kb) pregenomic RNA, along with that of other HBV RNAs 2.4, 2.1, and 0.8 kb in size, occurs in the nuclei of infected cells from a covalently closed circular (CCC) form of viral DNA by cellular RNA polymerase II (15, 29, 41, 55) ; these transcripts encode the nucleocapsid polypeptides, the large surface antigen polypeptides, the middle and major surface antigen polypeptides, and the X-gene polypeptide, respectively (15) . In addition, the 3.5-kb pregenomic RNA encodes the viral polymerase and is reverse transcribed by this polymerase within the viral nucleocapsid to produce the 3.2-kb viral genomic DNA (38) . Pregenomic RNA is packaged along with the viral polymerase into the core particles. DNA minus strands are synthesized by reverse transcription of the pregenomic RNA, with simultaneous degradation of pregenomic RNA. The minus-strand DNA serves as a template for plusstrand DNA synthesis. Nucleocapsid cores containing complete minus strands and partially complete plus strands acquire viral envelope proteins by budding into the lumen of the endoplasmic reticulum and are then transported out of the cell through the Golgi apparatus (21, 40, 57) .
One particularly important aspect of the HBV replication cycle is that mature nucleocapsids can also transport the viral genome back into the nucleus, where the partially doublestranded (DS) viral genome is converted into a transcriptionally functional CCC DNA. CCC DNA accumulation is regulated by viral envelope proteins in DHBV infections (26, 47, 48) and, presumably, in all hepadnavirus infections. CCC DNA is not covalently bound to protein and is detected in the nuclei of infected hepatocytes (31, 33) . CCC DNA can be detected in the nuclei of infected duck hepatocytes within 6 to 16 h after in vivo infection with DHBV and prior to expression of other viral RNA and DNA intermediates (31, 45, 50, 51) . The role of CCC DNA as a template for viral RNA synthesis is suggested by the observation that this DNA species and the relaxed circular (RC) form that lacks the terminal protein at the 5Ј end of the minus-strand DNA are apparently the only nuclear species present in chronically infected cells (45) . HBV CCC DNA is formed from RC DNA present in nucleocapsids after their entry into the cell nucleus either from the parental virions originating from outside the cell or from the pool of progeny nucleocapsids formed in the cytoplasm (53) . These two pathways yield 20 to 50 CCC DNA molecules per infected cell (33, 48, 53) . The 3.2-kb viral RC DNA is converted into CCC DNA by repair of the single-stranded (SS) gap, removal of 5Ј terminal structures (RNA and polymerase protein), covalent ligation of the strands, and supercoiling of the RC DNA into the CCC DNA form. Conversion of RC to CCC DNA in the liver is detected within 24 h following virus inoculation in the DHBV-duck liver model (31, 50) . The mechanism of DNA repair involved in this conversion is not known. However, specific inhibitors of HBV polymerase do not appear to interfere with CCC DNA formation after infection, implying that host cellular enzymes are sufficient to mediate this conversion (3, 24, 34) . The HBV CCC DNA molecule is highly stable.
The two anti-HBV drugs that were evaluated in the present study were lamivudine and clevudine (L-FMAU). Until recently, the only drug licensed for treatment of chronic HBV was alpha interferon (17, 52, 56) . Unfortunately, the overall response rate to alpha interferon is poor. During the past decade, synthesis of new biochemical nucleoside analogs has led to successful improvements in the use of nucleoside analogs for chronic HBV therapy. Lamivudine has been approved for HBV treatment (11, 20, 44) . L-FMAU is under preclinical investigation (5) and phase I-II evaluation (23) .
Our laboratory previously reported a novel transient in vitro system for studying HBV replication with the use of HBV recombinant baculovirus to efficiently deliver the HBV genome to HepG2 cells (9, 10) . Baculoviruses are extremely efficient vectors for gene delivery to hepatic cells (4, 43) . In HBV baculovirus-infected HepG2 cells, HBV gene expression is driven exclusively from endogenous promoters and HBV replication levels can be obtained that are markedly higher than those obtained from conventional HBV-expressing cell lines. HBV transcripts, intracellular and secreted HBV antigens, HBV DNA replicative intermediates (RI), and CCC HBV DNA are produced, and HBV virions are secreted. One of the advantages of the HBV baculovirus/HepG2 system is that the levels of HBV replication are sufficiently high that all forms of HBV DNA (RI, CCC, and extracellular) can be readily detected by Southern blot analysis. Indeed, the HBV baculovirus/HepG2 system is the only in vitro system with which it is possible to readily detect and quantify nuclear nonprotein-bound HBV DNA (9, 10) . Recently, Abdelhamed et al. also reported that the HBV recombinant baculovirus/ HepG2 system could be used to study the rebound phenomenon seen in humans and woodchucks after cessation of antiviral therapy (1) . Specifically, we quantified the relative time courses and magnitudes of disappearance of HBV DNA species involved in replication after drug therapy and the relative magnitudes of reappearance of HBV DNA species after cessation of drug treatment.
For this study, we report the development of a quantitative assay using the HBV recombinant baculovirus/HepG2 system for measuring 50% effective concentration (EC 50 ) and EC 90 values for treatment with antivirals not only for extracellular HBV DNA but also for different intracellular and nuclear forms of HBV DNA that participate in HBV replication. The main advantages of the baculovirus system are that (i) antivirals can be administered prior to initiation of HBV infection or after HBV infection and (ii) sufficiently high HBV replication levels are achieved to allow for the facile detection of individual HBV DNA species.
MATERIALS AND METHODS
Cell culture. The HepG2 cell line was maintained at 37°C in a humidified incubator at 5% CO 2 (22) . HepG2 cells were fed minimal essential medium (MEM; Gibco BRL, Gaithersburg, Md.) supplemented with 10% heat-inactivated fetal bovine serum (FBS; HyClone, Logan, Utah) (MEM-FBS). Sf21 insect cells were maintained in Grace's insect medium supplemented with yeastolate and lactalbumin hydrolysate (Gibco BRL) in a nonhumidified incubator at 28°C without CO 2 .
HBV baculovirus production and infection. The generation, amplification, and purification of the HBV baculovirus encoding a 1.3-U-length replication-competent HBV genome have been previously described (9) . The baculovirus infection procedure for HepG2 cells has also been previously described (9) . Briefly, HepG2 cells were seeded at approximately 20 to 40% confluency and allowed to attach and grow for 16 to 24 h prior to infection. On the day of infection, triplicate plates of cells were trypsinized and viable cell number was determined with a hemocytometer using trypan blue exclusion. Average cell counts were calculated and used to determine the volume of high-titered viral stock necessary to infect cells at the indicated multiplicity of infection (MOI). Baculovirus was diluted in MEM-FBS to achieve the appropriate MOI, using a volume of 1.0 or 0.5 ml to infect 100-or 60-mm-diameter dishes, respectively. Baculovirus was adsorbed to HepG2 cells for 1 h at 37°C with gentle rocking every 15 min to ensure that the inoculum was evenly distributed. The inoculum was then aspirated, and HepG2 cells were washed two times with phosphate-buffered saline and were refed MEM-FBS.
Analysis of intracellular RI. Cytoplasmic preparations containing HBV core particles were isolated from HepG2 cells. Cells were lysed with 0.5% NP-40 for 20 min. The cytoplasmic fraction was separated from the nuclear fraction by centrifugation. Unprotected DNA was removed by adjusting cytoplasmic preparations to 10 mM MgCl 2 -500 g of DNase I/ml (Roche Diagnostic Corporation, Indianapolis, Ind.) followed by 1 h of incubation at 37°C. To extract RI, EDTA, sodium dodecyl sulfate (SDS), NaCl, and proteinase K (Roche Diagnostic Corporation) were added separately and sequentially to final concentrations of 10 mM EDTA-1% SDS-100 mM NaCl-500 g proteinase K/ml. The sample was then incubated for 2 h at 37°C and afterward subjected to sequential phenol and chloroform extractions. DNA was precipitated with 0.1 vol of 3 M sodium acetate (NaAc) and 1 vol of isopropanol. Nucleic acid pellets were resuspended in a small volume of TE buffer (10 mM Tris, 1 mM EDTA) and digested with 100 g of RNase/ml (Roche Diagnostic Corporation) for 1 h at 37°C. RI were then analyzed by electrophoresis in 1% agarose gels followed by Southern blotting as previously described (42) . Nucleic acid hybridization was performed. A full-length DS HBV genome was used as a template to generate a 32 P-radiolabeled probe by using a Random Prime DNA labeling kit (Roche Diagnostic Corporation). HBV DNA bands were visualized and quantitated using a Phosphorimager and ImageQuant software (Molecular Dynamics, Sunnyvale, Calif.).
Detection of extracellular HBV DNA. Samples of conditioned medium were collected from HepG2 cells, centrifuged at 10,000 ϫ g for 10 min, and transferred to clean tubes to remove cellular debris. HBV particles were precipitated from samples of medium by using polyethylene glycol 8000 (Sigma Chemical Co., St. Louis, Mo.) as previously described (54) . Viral pellets were resuspended in phosphate-buffered saline, and DNA was extracted with lysis buffer (0.25% SDS, 0.25 M Tris, 0.25 M EDTA). The sample was then treated with proteinase K to achieve a final concentration of 500 g/ml. Digestion was allowed to proceed for 2 h at 37°C, after which the sample was subjected to sequential phenol and chloroform extractions. DNA was precipitated with 0.1 vol of 3 M NaAc and 1 vol of isopropanol. A total of 10 g of tRNA (Roche Diagnostic Corporation) was added as a carrier during precipitation. Nucleic acid pellets were resuspended in a small volume of TE buffer and were digested with 100 g of RNase/ml prior to analysis by electrophoresis and Southern blotting. HBV DNA bands were visualized and quantitated using a Phosphorimager and ImageQuant software.
Detection of non-protein-associated HBV DNA. Non-protein-bound circular HBV DNA was extracted from HepG2 cells by using a modification of a previously described procedure (47) . Nuclei were separated from the whole-cell lysate as described above for isolation of RI. The nuclear pellets were suspended in TE buffer (50:1), and the sample was then lysed with 4% SDS followed by precipitation with 2.5 M KCl. The supernatants were phenol and chloroform extracted, and nucleic acid was recovered by isopropanol precipitation. A total of 10 g of tRNA was added as a carrier during precipitation. Extracted nucleic acid was resuspended in water and digested with 100 g of RNase/ml and 30 U of Plasmid-Safe ATP-dependent DNase (Epicenter Technologies, Madison, Wis.) for 15 min at 37°C followed by 30 min of incubation at 65°C to inhibit the enzyme activity. Samples were analyzed by electrophoresis and Southern blotting. HBV DNA bands were visualized and quantitated using a Phosphorimager and ImageQuant software.
Lamivudine and L-FMAU treatment. 50 and EC 90 values. Cells were fed fresh drug-containing medium daily for 7 days, at which time point the experiments were terminated. Treatment was started 16 h before infection and continued during and after infection for 7 days (pretreatment schedule) or started 4 days p.i. and continued for 7 days (posttreatment schedule). (The term "pretreatment" is used in this report to describe exposure of cells to a drug prior to infection with HBV recombinant baculovirus and, hence, prior to initiation of HBV replication; the term "posttreatment" is used to describe treatment of cells with a drug after the cells are infected with HBV recombinant baculovirus and actively replicating HBV.) Calculation of EC 50 and EC 90 values. Specific HBV DNA species were analyzed by Southern blotting as described above. Amounts of HBV DNA were quantitatively measured using a Phosphorimager and ImageQuant software (Molecular Dynamics). Increasing concentrations of selected drugs were tested, with results that spanned the entire range from no response to complete response of HBV DNA. Drug concentrations were increased in constant log units. The best-fit sigmoid dose-response curve was generated using the drug concentration as the independent variable and the quantitative HBV DNA amount as the dependent variable using Prism 3.0 software (Graphpad, San Diego, Calif.). The EC 50 and the Hill coefficient values were calculated from the sigmoid dose-response curve. EC 90 values were calculated from the EC 50 value and the Hill coefficient using the following equation: 50 (1) where x ϭ 90 and H is the Hill coefficient. The duplicate zero concentration data for each antiviral response study are included for the digital images but not for the graphs and not for the EC 50 calculation. Statistical analyses. All experiments used triplicate samples for each treatment condition studied, and statistical analyses were done with JMP 3.0.2 software (SAS Institute, Cary, N.C.) using Student's t test. The null hypothesis was rejected for P values Յ 0.05. Unless otherwise stated, data are presented as averages Ϯ standard deviations (SD).
RESULTS

Effect of posttreatment with lamivudine on HBV replication.
Abdelhamed et al. previously demonstrated that the HBV baculovirus/HepG2 system has specific advantages for testing antiviral compounds (10) , including the ability to measure the effects of an antiviral on HBV DNA replication (extracellular, RI, and non-protein-bound nuclear HBV DNA) by Southern blot analysis. However, the conclusions reached in the previous study were based solely on qualitative analysis of Southern blot data. In the present study, the goal was to use a quantitative standardized method for evaluating the efficacy of specific antiviral agents for various steps of the HBV replication process and specific HBV DNA species. To achieve this goal, HBV DNA bands from Southern blots were detected by Phosphorimager and the data were analyzed by fitting to a sigmoid concentration curve with variable slope. In addition, 13 different drug concentrations were used and three independent experiments were carried out for each drug treatment study.
The time course for posttreatment was selected based on previous findings that HBV replication initiated in HepG2 cells by baculovirus infection reaches a plateau with regard to all aspects of HBV DNA production (extracellular HBV DNA, intracellular RI, and non-protein-bound nuclear HBV DNA) by 4 days p.i. At 1 day postseeding, HepG2 cells were infected with 100 PFU of HBV baculovirus/cell. Treatments with concentrations of lamivudine ranging from 0.001 to 16.8 M were initiated 4 days p.i. and continued daily for 7 days (the time point which coincided with 11 days p.i.). The untreated controls were also fed daily. At day 11 p.i., medium was harvested and analyzed for extracellular HBV DNA (Fig. 1A , D, and G). Concentration-dependent effects of posttreatment with lamivudine on HBV RI DNA (Fig. 1B , E, and H) and non-proteinbound HBV DNA (Fig. 1C , F, and I) were also measured; the time course and concentrations of lamivudine for these studies were the same as those described above for extracellular HBV DNA. Indeed, the experiments were designed such that the same cultures from which medium was collected for extracellular HBV DNA were harvested for RI and non-protein-bound HBV DNA. For RI, core particles were prepared from the cytoplasm and nucleic acid was extracted from the core particles. Non-protein-bound HBV DNA was isolated from the nuclei. HBV DNA bands of Southern blots for extracellular HBV DNA, intracellular RI, and non-protein-bound nuclear HBV DNA were detected by Phosphorimager. Three independent experiments were carried out, and the digital images of the Southern blot for extracellular HBV DNA for one of the three experiments are shown (Fig. 1A) . HBV DNA standards were included in each gel subjected to Southern blot analysis, thereby making it possible to quantitate the amount of HBV DNA. Data were analyzed for all three experiments and plotted as HBV extracellular DNA in picograms/culture/24 h against log lamivudine concentration. The plot determined for the data from the specific digital image in Fig. 1A is shown in Fig. 1D . The average extracellular HBV DNA values for all three experiments were also plotted in picograms/culture/24 h against log lamivudine concentration and are shown in Fig. 1G . It is important to note that the medium used for analysis of extracellular HBV DNA (virion production) was collected from cells fed fresh medium 24 h prior to harvesting and, as such, contained the amount of HBV DNA secreted over the previous 24-h period. For each step in the replication of HBV DNA, it was possible to quantify from the Southern blots not only total HBV DNA but also individual species of HBV DNA. To be thorough, we calculated extracellular HBV SS DNA as well as the RC-DS and total HBV DNA (although, as anticipated, extracellular HBV DNA migrated predominantly as the RC-DS form). Using gradient analysis, Delaney and Isom previously showed that in the HBV recombinant baculovirus/HepG2 system, extracellular HBV DNA comigrates predominantly with HBsAg at the density expected for enveloped Dane particles (9). The small amount of SS DNA in the secreted medium most likely represents unenveloped core particles devoid of HBsAg, a finding similar to that which Delaney and Isom reported in a previous study (9) . For this reason, EC 50 and EC 90 values were determined for extracellular RC-DS DNA, but not for SS DNA, and the average EC 50 and EC 90 values are shown in Table 1 .
The same methods used for analysis and presentation of FIG. 1. Effect of posttreatment with lamivudine on HBV replication. HepG2 cells were seeded in 60-mm-diameter dishes, infected with HBV recombinant baculovirus at 100 PFU/cell, and treated with different concentrations of lamivudine starting at 4 days p.i. Cells were daily fed fresh medium with or without the drug. Drug treatment was continued for 7 days, at which time the cells were harvested and the levels of HBV RI and non-protein-bound nuclear HBV DNA were determined. Samples of conditioned medium exposed to the infected cells for 24 h prior to harvest were collected 7 days after the initiation of treatment and assessed by Southern blot analysis for extracellular HBV DNA. Three independent experiments were carried out. HBV DNA bands were visualized using a Phosphorimager. Digital images of the Southern blots for a representative experiment are shown for HBV extracellular DNA (A), HBV RI DNA (B), and non-protein-bound HBV DNA (C). The concentrations of lamivudine used are also indicated. HBV DNA standards were included in each gel subjected to Southern blot analysis, thereby making it possible to quantitate the amount of HBV DNA. HBV DNA bands were visualized and quantitated using a Phosphorimager and ImageQuant software (Molecular Dynamics). The data from the Southern blots were analyzed for the representative experiment shown and plotted (in picograms/ culture/24 h against log lamivudine concentration) as HBV extracellular DNA (D), HBV RI DNA (E), and non-protein-bound HBV DNA (F). The average HBV DNA values for all three experiments were also determined and plotted (in picograms/culture/24 h against log lamivudine concentration) for HBV extracellular DNA (G), HBV RI DNA (H), and non-protein-bound HBV DNA (I). For each step in the replication of HBV DNA, it was possible to quantify from the Southern blots not only total HBV DNA but also individual species of HBV DNA. For HBV extracellular DNA, HBV DNA concentrations were calculated for RC-DS-SS (total) DNA ‫,)ء(‬ RC-DS DNA (OE), and SS DNA (). For HBV RI, HBV DNA concentrations were calculated for RC-DS-SS (total) DNA (E), RC-DS DNA (‚), and SS DNA (ᮀ). For non-protein-bound HBV DNA, HBV DNA concentrations were calculated for RC DNA (ࡗ) and CCC DNA (s). (Table 1) . Examination of the data on the effects of posttreatment with lamivudine on HBV replication resulted in the following determinations. (i) The levels of all extracellular, cytoplasmic, and nuclear HBV DNA species decreased with increasing drug concentrations. (ii) The average EC 50 and EC 90 values for extracellular RC-DS and RI RC-DS were remarkably similar.
(iii) The concentration-dependent effects of lamivudine on cytoplasmic SS HBV differ from the effects on the RC-DS replicative form. Examination of the digital image presenting the effects of lamivudine posttreatment on various forms of HBV RI (Fig. 1B) suggests that the SS species is more resistant than the RC-DS species. This finding is substantiated by the differences in the shapes of the two curves when the amount of HBV RI SS DNA plotted against the log of the lamivudine concentration is compared to the amount of HBV RI RC-DS DNA plotted against the log of the lamivudine concentration ( Fig.  1E and H) . Indeed, the average EC 90 value for lamivudine for the SS form was higher than that for the RC-DS form and statistical evaluation showed that the EC 90 value for the SS form was significantly greater than the EC 90 value for the RC-DS form (Table 1) . (iv) Nuclear HBV DNA is less sensitive to antiviral therapy, even at high drug concentrations, than are extracellular and cytoplasmic HBV DNA species (Fig. 1). (v) The concentration-dependent effects of lamivudine on nuclear HBV CCC DNA differ from the effects on the nuclear RC form (Fig. 1C) ; specifically, the nuclear CCC species of HBV DNA is considerably less sensitive to antiviral treatment than the nuclear RC species (Fig. 1C, F, and I) .
Effect of posttreatment with L-FMAU on HBV replication. Experiments were carried out as described above for lamivudine posttreatment, except the antiviral used was L-FMAU. At 1 day postseeding, HepG2 cells were infected with 100 PFU of HBV baculovirus/cell. Treatments with L-FMAU concentrations ranging from 0.0005 M to 29.8 M were initiated 4 days p.i. and continued daily for 7 days (the time point which coincided with 11 days p.i.). The untreated controls were also fed daily. At day 11 p.i., medium was harvested and analyzed for extracellular HBV DNA ( Fig. 2A, D, and G) . At day 11 p.i., cells were harvested for HBV RI DNA (Fig. 2B, E , and H) and non-protein-bound HBV DNA (Fig. 2C, F, and I ). For HBV extracellular DNA, HBV DNA concentrations were calculated for RC-DS-SS (total) DNA, RC-DS DNA, and SS DNA. For HBV RI, HBV DNA concentrations were calculated for RC-DS-SS (total) DNA, RC-DS DNA, and SS DNA. For nonprotein-bound HBV DNA, HBV DNA concentrations were calculated for RC DNA and CCC DNA. EC 50 and EC 90 values were determined for total HBV DNA and individual HBV DNA species (Table 1) .
Examination of the digital image and graphic data of the effects of posttreatment with L-FMAU on HBV DNA revealed many of the same findings as were observed for posttreatment with lamivudine, in particular, marked resistance of CCC DNA even at high concentrations of L-FMAU. The increased resistance of the intracellular SS DNA form of HBV RI that was seen after lamivudine treatment was also observed when the antiviral used for treatment was L-FMAU; the EC 50 value for the SS form was significantly greater than the EC 50 value for the RC-DS form ( Table 1) .
The data obtained in these studies made it possible not only to compare the effects of a single antiviral on different intracellular and nuclear forms of HBV DNA that participate in HBV replication but also to use the average EC 50 and EC 90 values to compare the effects of two different antivirals on various HBV DNA species. Evaluation of the effects of posttreatment with L-FMAU compared to those of posttreatment with lamivudine revealed one significant difference: the average EC 90 value for the RI RC-DS form was significantly greater for posttreatment with L-FMAU than posttreatment with lamivudine.
Effect of pretreatment with lamivudine on HBV replication. One of the advantages of the HBV recombinant baculovirus/ HepG2 system is that antiviral therapy can be administered prior to the initiation of HBV replication or at any time during 
FIG. 2.
Effect of posttreatment with L-FMAU on HBV replication. HepG2 cells were seeded in 60-mm-diameter dishes, infected with HBV recombinant baculovirus at 100 PFU/cell, and treated with different concentrations of L-FMAU starting at 4 days p.i. Cells were daily fed fresh medium with or without the drug. Drug treatment was continued for 7 days, at which time the cells were harvested and the levels of HBV RI and non-protein-bound nuclear HBV DNA were determined. Samples of conditioned medium exposed to the infected cells for 24 h prior to harvest were collected 7 days after the initiation of treatment and assessed by Southern blot analysis for extracellular HBV DNA. Three independent experiments were carried out. HBV DNA bands were visualized using a Phosphorimager. Digital images of the Southern blots for a representative experiment are shown for HBV extracellular DNA (A), HBV RI DNA (B), and non-protein-bound HBV DNA (C). The concentrations of L-FMAU used are also indicated. HBV DNA standards were included in each gel subjected to Southern blot analysis, thereby making it possible to quantitate the amount of HBV DNA. HBV DNA bands were visualized and quantitated using a Phosphorimager and ImageQuant software (Molecular Dynamics). The data from the Southern blots were analyzed for the representative experiment shown and plotted (in picograms/ culture/24 h against log L-FMAU concentration) as HBV extracellular DNA (D), HBV RI DNA (E), and non-protein-bound HBV DNA (F). The average HBV DNA values for all three experiments were also determined and plotted (in picograms/culture/24 h against log L-FMAU concentration) for HBV extracellular DNA (G), HBV RI DNA (H), and non-protein-bound HBV DNA (I). For each step in replication of HBV DNA, it was possible to quantify from the Southern blots not only total HBV DNA but also individual species of HBV DNA. For HBV extracellular DNA, HBV DNA concentrations were calculated for RC-DS-SS (total) DNA ‫,)ء(‬ RC-DS DNA (OE), and SS DNA (). For HBV RI, HBV DNA concentrations were calculated for RC-DS-SS (total) DNA (E), RC-DS DNA (‚), and SS DNA (ᮀ). For non-protein-bound HBV DNA, HBV DNA concentrations were calculated for RC DNA (ࡗ) and CCC DNA (s).
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on February 23, 2013 by PENN STATE UNIV http://aac.asm.org/ the replication process. This type of experiment cannot be carried out using the HepG2.2.15 cell line, which continuously expresses HBV. HepG2 cells were seeded in 60-mm-diameter dishes and infected with HBV recombinant baculovirus at 100 PFU/cell at 24 h after plating. Treatment with lamivudine was initiated 16 h prior to HBV baculovirus infection and continued during and after infection for 7 days. Cells were fed fresh medium with or without the drug daily. Three independent experiments were carried out. At day 7 p.i., medium was harvested and analyzed for extracellular HBV DNA (Fig. 3A, D , and G). At day 7 p.i., cells were harvested for HBV RI DNA (Fig. 3B, E , and H) and non-protein-bound HBV DNA (Fig.  3C , F, and I). For HBV extracellular DNA, HBV DNA concentrations were calculated for RC-DS-SS (total) DNA, RC-DS DNA, and SS DNA. For HBV RI, HBV DNA concentrations were calculated for RC-DS-SS (total) DNA, RC-DS DNA, and SS DNA. For non-protein-bound HBV DNA, HBV DNA concentrations were calculated for RC DNA and CCC DNA. EC 50 and EC 90 values were determined for total HBV DNA and individual HBV DNA species (Table  2) . A dramatic decrease in extracellular HBV DNA was observed when cells were treated with 0.02 M lamivudine. When treatment was with concentrations of lamivudine of 0.130 M and higher, extracellular HBV DNA was barely detectable. This dramatic decrease in the level of extracellular HBV DNA is readily apparent from the digital image (Fig. 3A) as well as the graph of the digital image (Fig. 3D ) and the graph of the averages of the data for all three experiments (Fig.  3G) .
Examination of the effects of pretreatment with lamivudine on cytoplasmic HBV DNA revealed that the levels of all RI species decreased with increasing drug concentrations but the SS form was more resistant than the RC-DS replicative form. In the experiment shown (Fig. 3B) , a marked decrease in the level of cytoplasmic RC-DS HBV DNA was first observed when cells were treated with 0.026 M lamivudine while the first major decline in levels of the SS species was seen when treatment was with 0.130 M lamivudine. It is also important that at high concentrations of lamivudine, the amount of cytoplasmic RC-DS HBV DNA fell to below detectable levels (Fig. 3B) . The different sensitivities of the cytoplasmic SS and RC-DS species to lamivudine are also evidenced by the difference in the shapes of the two curves when the amount of HBV RI SS DNA plotted against the log of the lamivudine concentration is compared to the amount of HBV RI RC-DS DNA plotted against the log of the lamivudine concentration ( Fig.  3E and H) . The average EC 50 and EC 90 values for the SS form were higher than for the RC-DS form, and statistical evaluation showed that the EC 90 value was significantly greater for the SS form than for the RC-DS form ( Table 2) .
Analysis of the figure showing the Southern blot of nuclear HBV DNA clearly revealed that pretreatment with lamivudine decreased the levels of both RC and CCC non-protein-bound DNA but that the magnitude of the effect was not as great as was observed for extracellular or cytoplasmic HBV DNA (Fig.  3C) . Indeed, nuclear HBV DNA was still detectable even after pretreatment with the highest concentrations of lamivudine used in the study. In addition, the CCC DNA species was more resistant to pretreatment with lamivudine than the RC DNA form.
Effect of pretreatment with L-FMAU on HBV replication. HepG2 cells were seeded in 60-mm-diameter dishes and infected with HBV recombinant baculovirus at 100 PFU/cell at 24 h after plating. Treatment with L-FMAU was initiated 16 h prior to HBV baculovirus infection and continued during and after infection for 7 days. Cells were daily fed fresh medium with or without the drug. Three independent experiments were carried out. At day 7 p.i., medium was harvested and analyzed for extracellular HBV DNA (Fig. 4A, D, and G) . At day 7 p.i., cells were harvested for HBV RI DNA (Fig. 4B, E, and H) and non-protein-bound HBV DNA (Fig. 4C, F, and I ). For HBV extracellular DNA, HBV DNA concentrations were calculated for RC-DS-SS (total) DNA, RC-DS DNA, and SS DNA. For HBV RI, HBV DNA concentrations were calculated for RC-DS-SS (total) DNA, RC-DS DNA, and SS DNA. For nonprotein-bound HBV DNA, HBV DNA concentrations were calculated for RC DNA and CCC DNA. EC 50 and EC 90 values were determined for total HBV DNA and individual HBV DNA species (Table 2) .
Pretreatment with L-FMAU was similar to pretreatment with lamivudine in that concentration-dependent decreases were seen for all extracellular and intracellular HBV DNA species (Fig. 4) . In addition, the cytoplasmic SS HBV DNA was more resistant than the RC-DS HBV DNA species (Fig.  4B, E, and H) . Statistical evaluation showed that the average EC 50 value was significantly greater for the cytoplasmic SS form than for the RC-DS form.
Evaluation of the effects of pretreatment with L-FMAU compared to those of pretreatment with lamivudine revealed one significant difference: the average EC 90 value for the cytoplasmic HBV RI DNA was significantly greater for pretreatment with L-FMAU than for pretreatment with lamivudine.
DISCUSSION
This report presents the development of a quantitative standardized assay that can be used to compare the effects of different HBV antivirals on production of different HBV DNA species that are generated during HBV replication. In addition, the effects of administering drugs prior to and during infection (pretreatment) can be compared to the effects of administering drugs at times when high levels of replication have been achieved (posttreatment). We concluded the following from the study. (i) Following antiviral treatment, the levels of HBV RI and extracellular DNA decrease in a concentration-dependent fashion. (ii) The EC 50 and EC 90 values and the Hill slopes differ for the different HBV DNA species being analyzed. (iii) Nuclear HBV DNAs are less sensitive to antiviral therapy than cytoplasmic or extracellular HBV DNAs. (iv) Nuclear HBV CCC DNA is less sensitive than the nuclear RC form.
We used the HBV recombinant baculovirus/HepG2 system to examine the effects of two different antivirals on three different portions of the HBV replication cycle: extracellular HBV DNA reflecting virion production, HBV RI DNA in the cytoplasm, and non-protein-bound nuclear HBV DNA. Many studies previously carried out to evaluate the potential efficacy of novel compounds for HBV replication or to compare sev- FIG. 3 . Effect of pretreatment with lamivudine on HBV replication. HepG2 cells were seeded in 60-mm-diameter dishes and infected with HBV recombinant baculovirus at 100 PFU/cell at 24 h after plating. Treatment with lamivudine was initiated 16 h prior to HBV baculovirus infection and continued during and after infection for 7 days. Cells were daily fed fresh medium with or without the drug. At 7 days p.i., the cells were harvested and the levels of HBV RI and non-protein-bound nuclear HBV DNA were determined. Samples of conditioned medium exposed to the infected cells for 24 h prior to harvest were collected 7 days p.i. and assessed by Southern blot analysis for extracellular HBV DNA. Three independent experiments were carried out. HBV DNA bands were visualized using a Phosphorimager. Digital images of the Southern blots for a representative experiment are shown for HBV extracellular DNA (A), HBV RI DNA (B), and non-protein-bound HBV DNA (C). The concentrations of lamivudine used are also indicated. HBV DNA standards were included in each gel subjected to Southern blot analysis, thereby making it possible to quantitate the amount of HBV DNA. HBV DNA bands were visualized and quantitated using a Phosphorimager and ImageQuant software (Molecular Dynamics). The data from the Southern blots were analyzed for the representative experiment shown and plotted (in picograms/culture/24 h against log lamivudine concentration) as HBV extracellular DNA (D), HBV RI DNA (E), and non-protein-bound HBV DNA (F). The average HBV DNA values for all three experiments were also determined and plotted (in picograms/culture/24 h against log lamivudine concentration) for HBV extracellular DNA (G), HBV RI DNA (H), and non-protein-bound HBV DNA (I). For each step in replication of HBV DNA, it was possible to quantify from the Southern blots not only total HBV DNA but also individual species of HBV DNA. For HBV extracellular DNA, HBV DNA concentrations were calculated for RC-DS-SS (total) DNA ‫,)ء(‬ RC-DS DNA (OE), and SS DNA (). For HBV RI, HBV DNA concentrations were calculated for RC-DS-SS (total) DNA (E), RC-DS DNA, (‚) and SS DNA (ᮀ). For non-protein-bound HBV DNA, HBV DNA concentrations were calculated for RC DNA (ࡗ) and CCC DNA (s). Using the HBV recombinant baculovirus/HepG2 system to quantitatively evaluate concentration-dependent effects of antivirals on HBV RI generated novel information that was not obtained previously using other HBV in vitro cell culture systems. Before discussing the novel information obtained, it is first important to realize what the system measures. The endpoint for HBV RI is quite different than was measured for extracellular HBV DNA. Specifically, the level of HBV DNA represents the amount of HBV DNA present in the cytoplasm of the cell at the time of harvest and, as such, reflects a combination of the effects of blocked or decreased synthesis as a result of antiviral therapy as well as the natural turnover or half-life of each HBV DNA species. One issue that was addressed in this study was that of whether EC 50 and EC 90 values for total HBV RI are the same as or differ from those obtained for the SS and/or RC-DS HBV DNA species. Digital imaging of HBV DNA bands from Southern blot analyses revealing the high levels of HBV replication that occur when using the baculovirus system made it possible to address this issue.
The most dramatic but not unexpected result observed in this study was that of the resistance of HBV CCC DNA to antiviral therapy even at high concentrations of lamivudine or L-FMAU. It is well established that hepadnavirus CCC DNAs are highly stable and resistant to antiviral therapy. These findings stem from studies carried out with DHBV in primary duck hepatocytes and in ducklings (2, 36) and with woodchuck hepatitis virus in woodchucks (7, 18, 30, 34) . It is also assumed that HBV CCC DNA is highly resistant to lamivudine, based on findings with humans (25, 44) . Specifically, HBV DNA reappears in the serum of patients after cessation of lamivudine therapy and this rebound is assumed to be due to the persistence of a highly stable drug-resistant HBV CCC DNA form in nuclei of human hepatocytes. However, researchers have not been able to evaluate previously in a cell culture system the question of whether HBV CCC DNA is resistant to antivirals. Because high levels of nuclear HBV DNA are produced in HepG2 cells in which HBV replication has been initiated by infection with a recombinant HBV baculovirus (9, 10) , it was possible using this system to carry out, for the first time, detailed quantitative analyses of the effects of treatment with antivirals on nuclear HBV DNA levels. It was also possible to quantitatively analyze the effects of treatment on HBV RC DNA separately from those on HBV CCC DNA. Examination of the data revealed that the CCC DNA form of nuclear HBV DNA is highly resistant to treatment with lamivudine or L-FMAU whether the antiviral was used in a pretreatment or posttreatment protocol. The high level of resistance is particularly noteworthy when taking into account the multiple concentrations of each antiviral used as well as the large concentration range included in the study. It is clear that the HBV CCC DNA molecule is highly stable. Indeed, it is possible that the only way to eliminate HBV CCC DNA from a hepatocyte is for that hepatocyte to die. However, if a drug could be developed that interferes with the formation and/or stability of HBV CCC DNA, the efficacy of that drug could be easily tested using the assay described in this paper.
One characteristic of the HBV recombinant baculovirus/ HepG2 system that is particularly pertinent to the present study is the ability to synchronously initiate high levels of HBV replication such that cells can be treated with an antiviral prior to or at any specified time after initiation of HBV replication. Cell lines stably expressing HBV, such as HepG2.2.15 cells, cannot be used for measuring the effects of treatment with an antiviral prior to initiation of infection, because these cells continuously shed HBV and contain HBV DNA and gene products at all phases of the replication cycle. The effects of pretreatment with an antiviral can be measured in HepG2 cells transiently transfected with plasmid HBV DNA. However, the percentage of cells positive for HBV expression when HepG2 cells are transfected using classical methods is low. In an initial description of the HBV recombinant baculovirus/HepG2 system, Delaney and Isom not only demonstrated that levels of HBV gene expression and replication can be achieved that far exceed the levels found in HepG2.2.15 cells but also showed that strong HBcAg staining was detected in at least 75% to 85% of the cells when infection was at a MOI of 100 PFU/cell (9). Delaney and Isom showed in their original study that high levels of HBV replication can be maintained for at least 11 days p.i. More recently, Abdelhamed et al. have reported that high levels of HBV replication can be maintained for 35 days p.i. (1) . This long plateau of HBV replication makes it possible to easily compare the effects of antiviral therapy on HBV replication by either a pretreatment or a posttreatment protocol. 4 . Effect of pretreatment with L-FMAU on HBV replication. HepG2 cells were seeded in 60-mm-diameter dishes and infected with HBV recombinant baculovirus at 100 PFU/cell at 24 h after plating. Treatment with L-FMAU was initiated 16 h prior to HBV baculovirus infection and continued during and after infection for 7 days. Cells were daily fed fresh medium with or without the drug. At 7 days p.i., the cells were harvested and the levels of HBV RI and non-protein-bound nuclear HBV DNA were determined. Samples of conditioned medium exposed to the infected cells for 24 h prior to harvest were collected 7 days p.i. and assessed by Southern blot analysis for extracellular HBV DNA. Three independent experiments were carried out. HBV DNA bands were visualized using a Phosphorimager. Digital images of the Southern blots for a representative experiment are shown for HBV extracellular DNA (A), HBV RI DNA (B), and non-protein-bound HBV DNA (C). The concentrations of L-FMAU used are also indicated. HBV DNA standards were included in each gel subjected to Southern blot analysis, thereby making it possible to quantitate the amount of HBV DNA. HBV DNA bands were visualized and quantitated using a Phosphorimager and ImageQuant software (Molecular Dynamics). The data from the Southern blots were analyzed for the representative experiment shown and plotted (in picograms/ culture/24 h against log L-FMAU concentration) as HBV extracellular DNA (D), HBV RI DNA (E), and non-protein-bound HBV DNA (F). The average HBV DNA values for all three experiments were also determined and plotted (in picograms/culture/24 h against log L-FMAU concentration) for HBV extracellular DNA (G), HBV RI DNA (H), and non-protein-bound HBV DNA (I). For each step in replication of HBV DNA, it was possible to quantify from the Southern blots not only total HBV DNA but also individual species of HBV DNA. For HBV extracellular DNA, HBV DNA concentrations were calculated for RC-DS-SS (total) DNA ‫,)ء(‬ RC-DS DNA (OE), and SS DNA(). For HBV RI, HBV DNA concentrations were calculated for RC-DS-SS (total) DNA (E), RC-DS DNA (‚), and SS DNA (ᮀ). For non-protein-bound HBV DNA, HBV DNA concentrations were calculated for RC DNA (ࡗ) and CCC DNA (s).
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Several nucleoside analogs are presently undergoing investigation as potential anti-HBV agents. Both lamivudine and L-FMAU are pyrimidine analogs that belong to a nucleoside family with a nonnatural levorotatory configuration (L-nucleoside analogs). Compared to their dextrorotatory counterparts, the L-nucleoside analogs exhibit very potent activity against HBV without significant toxicity (35) . Clinical data have shown that lamivudine treatment rapidly reduces the levels of HBV DNA, is well tolerated, and improves liver histology (16, 25, 37) . In general, the anti-HBV nucleoside analogs mainly interfere with enzymatic function(s) of the HBV DNA polymerase. Their antiviral activity requires intracellular phosphorylation to the corresponding deoxynucleoside triphosphate (dNTP) equivalent. When the dNTP analog is accepted as a substrate by the HBV polymerase, it can be polymerized onto the 3Ј-hydroxy (OH) terminus of the nascent DNA chain. When an incorporated dNTP analog, such as lamivudine, lacks a 3Ј-OH group, the growing chain terminates immediately. Using endogenous reverse transcriptase reactions of viral core particles from duck liver and serum, it has been shown that lamivudine triphosphate acts as a chain terminator for the DNA polymerase activities (46) .
L-FMAU was first described as a potent antiviral agent against HBV and Epstein-Barr virus (6) . In contrast to its D-enantiomers, L-FMAU did not interfere with mitochondrial functions and showed no significant bone marrow toxicity at concentrations up to 100 M in vitro. L-FMAU did not show any cytotoxicity at concentrations up to 200 M for the HepG2 2.2.15 cell line (13, 39) . In DHBV-infected ducklings, treatment with 40 mg of L-FMAU/kg of body weight produced no toxic side effects (2) . In preliminary in vivo toxicity studies in mice for 30 days (50 mg/kg/day) or in woodchucks for 3 months (10 mg/kg/day), L-FMAU did not show any apparent toxicity and no significant abnormalities of clinical chemistry were observed (F. Zoulim, S. Aguesse, C. Borel, C. Trepo, and Y.-C. Cheng, Abstr. 9th Int. Conf. Antivir. Res., 30:A24, 1996). L-FMAU was shown to exhibit potent in vivo antiviral activity in woodchucks chronically infected with woodchuck HBV and is currently under investigation for use in the treatment of humans (5, 23) . Although L-FMAU induces a rapid decrease in HBV nucleic acid levels in a dose-dependent fashion, the exact mechanism of action of L-FMAU is not yet clear (23) . L-FMAU is phosphorylated stepwise in cells to its mono-, di-, and triphosphate forms by cellular enzymes (27, 39) . In one study, the mechanism of inhibition by L-FMAU triphosphate of the synthesis of viral minus-strand DNA was analyzed using an in vitro assay for the expression of an enzymatically active DHBV reverse transcriptase (2) . The data obtained indicated that L-FMAU triphosphate exhibits an inhibitory effect on the incorporation of dAMP in the viral DNA primer. Incorporation of analogs that possess a functional dNTP 3Ј-OH equivalent, such as L-FMAU, may cause delayed arrest of replication as a result of formation either of a dead-end complex with an incoming dNTP complementary to the next template position or of template distortion or miscoding at a later stage; for example, penciclovir and ganciclovir have both been shown to cause delayed chain termination after incorporation by herpesvirus or cellular polymerases (12, 19) . Indeed, L-FMAU may function similarly.
We report here a detailed study of the effects of lamivudine and L-FMAU on HBV replication. We have been able to ask questions not previously addressed, generate novel data regarding the effects of each of these drugs on specific aspects of HBV replication, and address these questions independently for administration of the drug posttreatment (4 days p.i.) as well as pretreatment. In this study, EC 50 and EC 90 values were determined; these values can be used to compare the effects of a specific antiviral on different steps in the HBV replication cycle and on different HBV species (such as nuclear RC and nuclear CCC species). The above listed parameters can be determined and compared for two or more drugs. As is true for any drug-testing system of this nature, it would be inappropriate to expect to be able to compare EC 50 and EC 90 values determined in the HBV recombinant baculovirus system as defined in this paper to those determined in a different in vitro cell culture system, such as a system based on the use of HepG2. The experiments presented in this study have also extended our knowledge regarding the capabilities and uses of the HBV recombinant baculovirus/HepG2 system. We have shown that the effects of antivirals on all HBV DNA species produced during replication can be evaluated separately and quantitatively with a Phosphorimager to visualize HBV DNA bands obtained by Southern blot analysis. We have demonstrated that all data, including effects on HBV extracellular DNA, HBV RI DNA, and nuclear HBV DNA, can be obtained from a single plate of HepG2 cells; this method is not only cost efficient but could also lead to more appropriately controlled experiments.
The experiments carried out in this study have advanced our understanding of the antiviral activity of lamivudine and L-FMAU. We have been able to use the EC 50 and EC 90 values to further understand the antiviral activity of each drug (lamivudine and L-FMAU) alone and also to compare the activities of the two drugs. Whether the antiviral used was lamivudine or L-FMAU and whether the antiviral was used in a pretreatment or posttreatment protocol, the cytoplasmic SS HBV DNA species was more resistant to antiviral therapy than the RC-DS form. When the effects of lamivudine and L-FMAU were compared, surprisingly few differences were found. Evaluation of the effects of posttreatment with L-FMAU compared to those of posttreatment with lamivudine revealed one significant difference: the average EC 90 value for the RI RC-DS form was significantly greater for posttreatment with L-FMAU than posttreatment with lamivudine. Similarly, evaluation of the effects of pretreatment with L-FMAU compared to those of pretreatment with lamivudine revealed only one significant difference: the average EC 90 value for the cytoplasmic HBV total RI DNA was significantly greater for pretreatment with L-FMAU than pretreatment with lamivudine. We conclude that the system described in this report can be used to evaluate the efficacy of any potential anti-HBV drug.
